Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) traded down 5.8% during trading on Friday . The stock traded as low as $80.57 and last traded at $80.79. 475,390 shares changed hands during trading, a decline of 48% from the average session volume of 916,270 shares. The stock had previously closed at $85.78.
Analyst Ratings Changes
A number of brokerages have commented on PCVX. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Leerink Partners lifted their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. BTIG Research upped their price objective on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Bank of America raised their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Finally, Mizuho upped their price target on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte currently has a consensus rating of "Buy" and a consensus price target of $145.71.
Get Our Latest Stock Analysis on Vaxcyte
Vaxcyte Trading Down 5.6 %
The business has a 50 day moving average of $95.66 and a 200-day moving average of $92.59. The stock has a market cap of $10.09 billion, a PE ratio of -17.60 and a beta of 0.94.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the business earned ($0.91) EPS. Research analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.
Insider Activity
In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,720,610.98. The trade was a 6.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 7,098 shares of the company's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $109.21, for a total transaction of $775,172.58. Following the transaction, the chief executive officer now owns 138,581 shares of the company's stock, valued at approximately $15,134,431.01. The trade was a 4.87 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 117,830 shares of company stock valued at $12,383,030. Insiders own 3.10% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in PCVX. Riverview Trust Co purchased a new stake in shares of Vaxcyte during the 3rd quarter worth $27,000. Blue Trust Inc. boosted its holdings in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after buying an additional 93 shares in the last quarter. Quest Partners LLC acquired a new position in Vaxcyte during the second quarter worth about $70,000. Meeder Asset Management Inc. lifted its position in shares of Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after acquiring an additional 635 shares during the period. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $92,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Stories
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
